AWAgneta Wikman

Agneta Wikman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Agneta Wikman has a total of 688 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hospital‐wide massive transfusion over time: Indications, treatment strategies, and clinical outcomes

    by Anna Gustafsson, Carl‐Magnus Wahlgren, Mattias Günther, Ivette Raices Cruz, Agneta Wikman

    Background and Objectives: Massive transfusion (MT) is a lifesaving intervention for severe hemorrhage. Contemporary data on indications, transfusion practices, and outcomes across a broad in‐hospital population remain limited. Materials and Methods: This retrospective cohort study included adult patients receiving MT at Karolinska University Hospital between 2016 and 2021. MT was defined as transfusion of ≥10 red blood cell (RBC) units within 24 h. Data were obtained from the hospital transfusion registry and medical records. Results: A total of 486 MT events were identified. Median age was 60 years (interquartile range [IQR] 46–70), and 65.6% of patients were male. The most common indications were trauma (15.6%), abdominal cancer surgery (15.0%), cardiothoracic surgery (14.0%), and vascular surgery (12.3%). The overall median RBC:plasma:platelet ratio was 5:5:1, consistent with balanced transfusion strategies. MT was more frequently associated with acute than elective procedures (67.2% vs. 32.8%, p < 0.001). Fibrinogen, tranexamic acid, and prothrombin complex concentrate were administered in 69.5%, 52.1%, and 13.6% of cases, respectively. Mortality was 10.3% at 24 h and 31.7% at 30 days. The annual number of MT events decreased significantly during the study period ( p < 0.001), corresponding to an approximately 40% reduction between 2016 and 2021. Conclusion: MT was required across a wide range of surgical and medical specialties and remained associated with substantial mortality. Balanced transfusion strategies were well implemented, whereas the use of adjunct hemostatic therapies varied considerably. The marked reduction in MT events over time suggests improvements in hemorrhage management and bleeding control.

  • Open Access

    How to deal with emergency preparedness

    by W. Martin Smid, Claudia S. Cohn, Agneta Wikman, Nelson H. Tsuno

  • Open Access

    Discordant prenatal and postnatal RhD typing caused by a novel RHD frameshift variant (c.540del; p. Leu181CysfsTer48 ) in Swedish individuals

    by Ahlam Badri, Dan Gratschev, Tove Johansson, Agneta Wikman, Tesfai Emahazion

    Background and Objectives: Non‐invasive prenatal testing (NIPT) for fetal RHD genotyping is widely used to guide anti‐D prophylaxis, but discrepancies between predicted fetal RhD status and postnatal serological typing can occur due to variant RHD alleles. This study aimed to confirm and characterize a suspected novel exon 4 deletion in RHD using multiple molecular methods and to assess inheritance. Materials and Methods: NIPT predicted an RhD‐positive fetus in an RhD‐negative pregnant woman, whereas postnatal serology showed an RhD‐negative phenotype. Molecular analysis of RHD was performed using the RBC‐Ready Gene CDE kit (Inno‐Train, Kronberg, Germany), targeted next‐generation sequencing (NGS) and Sanger sequencing in the family and in an unrelated RhD‐negative woman. Results: Targeted NGS identified a single‐nucleotide deletion in the RHD gene (c.540del), predicted to result in a frameshift and premature termination (p.Leu181CysfsTer48). Sanger sequencing confirmed the variant in the newborn and demonstrated paternal inheritance, with the father heterozygous for the deletion. The same variant was also identified in an unrelated RhD‐negative woman of Swedish origin; notably, the newborn's father was also of Swedish origin. Conclusion: This case illustrates a limitation of current NIPT approaches, which detect RHD sequences but not gene functionality. Molecular follow‐up is crucial in cases of discordant RhD typing.

  • Open Access

    Coagulation and platelet function in cold‐stored whole blood on missions in a helicopter emergency service

    by José‐Gabriel Sato Folatre, Agneta Wikman, Vladimir Radulovic, Göran Sandström, Gabriel Skallsjö, Per Arnell, Sven‐Erik Ricksten, Birgitta Romlin

    Background: Haemorrhage is a leading cause of morbidity and mortality in trauma, and prehospital transfusion of blood products is often necessary. Whole blood has been proposed to be the best alternative, but it is unclear whether, and how, storage and transport of the blood in a helicopter affects the blood units. We investigated the coagulation capacity and platelet function in whole blood at different time points during helicopter missions.Methods: Twenty units of low‐titre group O RhD negative whole blood were collected from healthy volunteers and analysed before, during and after transport in a helicopter. Coagulation and platelet function, as measured by thromboelastography, and blood samples for pH, electrolytes, glucose and lactate were assessed at baseline and 24, 72 and 168 h after storage in the helicopter. Plasma concentrations of coagulation factors and haemoglobin and blood counts were measured at baseline and after 168 h.Results: Plasma concentrations of coagulation factors and haemoglobin did not change during storage and transport. Platelet counts decreased from a baseline mean of 172 ± 29 × 109/L to a mean of 120 ± 28 × 109/L after 168 h, and platelet function worsened slightly but significantly by 8%–9% during storage and transport. pH and glucose decreased while potassium and lactate levels increased after 168 h compared with baseline.Conclusion: Storage and transport of whole‐blood units in a rescue helicopter, for up to 168 h, had a slight impact on the blood quality. Storage of whole blood on board of the helicopter holds up to European standard, measured as temperature and haemolysis.


  • Potential of a Second Screening Test for Alloimmunization in Pregnancies of Rhesus-positive Women: A Swedish Population-based Cohort Study

    by Nishan Lamichhane, Shengxin Liu, Agneta Wikman, Marie Reilly

    Introduction: There is lack of consensus regarding whether a second screening in rhesus-positive pregnant women is worthwhile, with different guidelines, recommendations, and practices. We aimed to estimate the number and timing of missed alloimmunizations in rhesus-positive pregnancies screened once and weigh the relative burden of additional screening and monitoring versus the estimated reduction in adverse pregnancy outcomes. Methods: We extracted information on maternal, pregnancy, and screening results for 682,126 pregnancies for 2003–2012 from Swedish national registers. We used data from counties with a routine second screening to develop and validate a logistic model for a positive second test after an earlier negative. We used this model to predict the number of missed alloimmunizations in counties offering only one screening. Interval-censored survival analysis identified an optimal time window for a second test. We compared the burden of additional screening with estimated adverse pregnancy outcomes avoided. Results: The model provided an accurate estimate of positive tests at the second screening. For counties with the lowest screening rates, we estimated that a second screening would increase the alloimmunization prevalence by 33% (from 0.19% to 0.25%), detecting the 25% (304/1222) of cases that are currently missed. The suggested timing of a second screen was gestational week 28. For pregnancies currently screened once, the estimated cost of a second test followed by maternal monitoring was approximately 10% of the cost incurred by the excess adverse pregnancy outcomes. Conclusion: Investment in routine second screening can identify many alloimmunizations that currently go undetected or are detected late, with the potential for cost savings.

  • International Forum on Home‐Based Blood Transfusion: Responses

    by Briony Shaw, Erica Wood, Zoe McQuilten, Jeannie Callum, Iñigo Romon, Pedro Sanroma, Dora Garcia, Philip Crispin, Lilian Castilho, Jose Mauro Kutner, et al.

  • Open Access

    Recommendation for validation and quality assurance of non‐invasive prenatal testing for foetal blood groups and implications for IVD risk classification according to EU regulations

    by Frederik Banch Clausen, Åsa Hellberg, Gregor Bein, Peter Bugert, Dieter Schwartz, Tadeja Dovc Drnovsek, Kirstin Finning, Katarzyna Guz, Katri Haimila, Christine Henny, et al.

    Background and Objectives: Non‐invasive assays for predicting foetal blood group status in pregnancy serve as valuable clinical tools in the management of pregnancies at risk of detrimental consequences due to blood group antigen incompatibility. To secure clinical applicability, assays for non‐invasive prenatal testing of foetal blood groups need to follow strict rules for validation and quality assurance. Here, we present a multi‐national position paper with specific recommendations for validation and quality assurance for such assays and discuss their risk classification according to EU regulations.Materials and Methods: We reviewed the literature covering validation for in‐vitro diagnostic (IVD) assays in general and for non‐invasive foetal RHD genotyping in particular. Recommendations were based on the result of discussions between co‐authors.Results: In relation to Annex VIII of the In‐Vitro‐Diagnostic Medical Device Regulation 2017/746 of the European Parliament and the Council, assays for non‐invasive prenatal testing of foetal blood groups are risk class D devices. In our opinion, screening for targeted anti‐D prophylaxis for non‐immunized RhD negative women should be placed under risk class C. To ensure high quality of non‐invasive foetal blood group assays within and beyond the European Union, we present specific recommendations for validation and quality assurance in terms of analytical detection limit, range and linearity, precision, robustness, pre‐analytics and use of controls in routine testing. With respect to immunized women, different requirements for validation and IVD risk classification are discussed.Conclusion: These recommendations should be followed to ensure appropriate assay performance and applicability for clinical use of both commercial and in‐house assays.


  • International Forum on Walking Blood Bank Programmes: Summary

    by Christophe Martinaud, Tom Scorer, Miquel Lozano, Andrew Miles, Gary Fitchett, Alhassane Ba, Agneta Wikman, Patrik Nimberger‐Hansson, Stefan Enbuske, Miloš Bohoněk, et al.


  • International Forum on Walking Blood Bank Programmes: Responses

    by Christophe Martinaud, Tom Scorer, Miquel Lozano, Andrew Miles, Gary Fitchett, Alhassane Ba, Agneta Wikman, Patrik Nimberger‐Hansson, Stefan Enbuske, Miloš Bohoněk, et al.


  • Open Access

    Altered strategy of prophylactic anti‐D administration in pregnancy to cover term and post‐term – a pilot study

    by Agneta Wikman, Anette Mörtberg, Elisabeth Jalkesten, Yvonne Jansson, Anita Karlsson, Eleonor Tiblad, Gunilla Ajne

    Background and objective Routine antenatal anti‐D prophylaxis (RAADP) to RhD‐negative women is most often administered in gestational age (GA) 28–30 weeks with the next anti‐D dose administered postpartum. The aim of this study was to analyse the proportion of RhD‐negative women where RAADP is not detectable at term and in a pilot study to investigate whether RAADP administered in GA 28 and 38 results in detectable levels at term, post‐term and post‐delivery. Materials and methods In a retrospective analysis, 4280 RhD‐negative women carrying an RHD positive fetus were included and the proportion with a negative antibody screen at delivery was determined. In the second part, 39 pregnancies were included prospectively, a second dose of RAADP was administered in GA 38 weeks, and anti‐D was quantified before the second dose and then weekly for 5 weeks. Results In the retrospective analysis, 20·5% (856/4280) with RAADP administered in GA 28 were negative in routine antibody screening at delivery. In the small prospective study, 18% (7/39) had a negative antibody screen and 26% (10/39) had levels below 0·005 IU/ml, in the quantification assay, in GA 38. Anti‐D prophylaxis administered in GA 38 showed detectable levels of anti‐D up to 30 days post‐delivery, with concentration at delivery 0·060 ± 0·034 IU/ml (mean ± SD). Conclusion Approximately 20% of the RhD‐negative women show non‐detectable levels of anti‐D at term. A second dose of RAADP at GA 38 results in stable concentrations of anti‐D at term, post‐term and post‐delivery, but with large interindividual variation.